`
`First Named Inventor: Tomas SCHWARZ
`
`Confirmation No.: 4180
`
`Applicant: BTL Medical Solutions A.S.
`
`Art Unit: 3791
`
`Application No.: 16/915,640
`
`Examiner: Samuel G. GILBERT
`
`Filing Date: June 29, 2020
`
`Atty. Docket: 4387.00400H0
`
`Title: AESTHETIC METHOD OF BIOLOGICAL STRUCTURE TREATMENTBY
`MAGNETIC FIELD
`
`Supplemental Information Disclosure Statement
`
`Mail Stop Issue Fee
`
`Commissioner for Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed on accompanying IDS Forms PTO/SB/08a orits equivalent and/or PTO/SB/08borits
`
`equivalent are documents that may be considered material to the patentability of this application as
`
`defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R.
`
`§§ 1.97 and 1.98.
`
`Applicant haslisted dates on the attached IDS Formsbased on information presently
`
`available to the undersigned. However, the listed dates should not be construed as an admission that
`
`the information was actually published on the date indicated.
`
`Applicant reserves the right to establish the patentability of the claimed invention over any
`
`of the information provided herewith, and/or to prove that this information maynotbe priorart,
`
`and/or to prove that this information may not be enabling for the teachings purportedly offered.
`
`
`
`-2-
`
`BTL MEDICAL SOLUTIONSA:S.
`Application No.: 16/915,640
`
`This statement should not be construed as a representation that a search has been made, or
`
`that information more material to the examination of the present patent application does notexist.
`
`The Examineris specifically requested not to rely solely on the material submitted herewith.
`
`Filing under 37 C.F.R. § 1.97(d) This Information Disclosure Statementis being filed more
`
`than three monthsafter the U.S. filing date and after the mailing date of a Final Rejection or Notice
`
`of Allowance, but on or before payment of the Issue Fee. The required fee is provided through
`
`online credit card paymentauthorization in the amount of $260.00 in paymentof the fee under 37
`
`C.F.R. § 1.17(p); in addition:
`
`Statement under 37 C.F.R. § 1.97(e)(2). [hereby state that no item of information in this
`
`Information Disclosure Statement was cited in a communication from a foreign patent office in a
`
`counterpart foreign application and, to my knowledge after making reasonable inquiry, was known
`
`to any individual designated in 37 C.F.R. § 1.56(c) more than three monthspriorto thefiling of this
`
`Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
`
`Copies of documents FP1-FP6 and NPL1 are submitted. However, in accordance with 37
`
`C.F.R. § 1.98(a)(2)(11), no copies of U.S. patents and patent application publications cited as
`
`documents US1-US9 onthe attached IDS Forms are submitted.
`
`It is expected that the examiner will review the prosecution and cited art in the parent
`
`applications in accordance with MPEP 2001.06(b), and indicate in the next communication from the
`
`office that the art cited in the earlier prosecution history has been reviewed in connection with the
`
`present application.
`
`Atty. Dkt. No. 4387.00400H0
`
`
`
`-3-
`
`BTL MEDICAL SOLUTIONSA:S.
`Application No.: 16/915,640
`
`It is respectfully requested that the Examinerinitial and return a copy of the enclosed IDS
`
`Forms, and indicate in the official file wrapper of this patent application that the documents have
`
`been considered.
`
`The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or
`
`credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`KAID Cl.
`
`Richard D. Coller III
`Attorney for Applicant
`Registration No. 60,390
`
`Date: August 11, 2022
`
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`18806047.1
`
`Atty. Dkt. No. 4387.00400H0
`
`